A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some side effects common to other antidepressants.
Background Self-harm and suicide are common among prison inmates, but less is known about these phenomena in those with psychosis. Objectives The aim of this study was to examine self-harm behaviour ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback